ChiCTR2400085045 版本V1.0 版本创建时间2024/05/30 10:29:52 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2400085045 

最近更新日期:

Date of Last Refreshed on:

2024-05-30 10:29:47 

注册时间:

Date of Registration:

2024-05-30 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

老年呼吸系感染多维度长程预后评估及干预策略研究

Public title:

A study of multidimensional long-term prognostic assessment and intervention strategies for respiratory infections in the elderly

注册题目简写:

English Acronym:

研究课题的正式科学名称:

老年呼吸系感染多维度长程预后评估及干预策略研究

Scientific title:

A study of multidimensional long-term prognostic assessment and intervention strategies for respiratory infections in the elderly

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

翁冰绚 

研究负责人:

李燕明 

Applicant:

Binging Weng 

Study leader:

Yanming Li 

申请注册联系人电话:

Applicant telephone:

+86 136 0254 4318

研究负责人电话:

Study leader's telephone:

+86 136 0254 4317

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

Anita_weng@163.com

研究负责人电子邮件:

Study leader's E-mail:

lymyl@263.net

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

北京东单大华路1号

研究负责人通讯地址:

北京东单大华路1号

Applicant address:

1 Dahua Road, Dongdan, Beijing

Study leader's address:

1 Dahua Road, Dongdan, Beijing

申请注册联系人邮政编码:

Applicant postcode:

100020

研究负责人邮政编码:

Study leader's postcode:

100020

申请人所在单位:

北京医院

Applicant's institution:

Beijing Hospital

研究负责人所在单位:

北京医院

Affiliation of the Leader:

Beijing Hospital

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2024BJYYEC-KY081-02

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

北京医院伦理委员会

Name of the ethic committee:

Beijing Hospital Ethics Committee

伦理委员会批准日期:

Date of approved by ethic committee:

2024-05-22 00:00:00

伦理委员会联系人:

侯文静

Contact Name of the ethic committee:

Wenjing Hou

伦理委员会联系地址:

北京东单大华路1号

Contact Address of the ethic committee:

1 Dahua Road, Dongdan, Beijing

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 136 0254 4317

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

北京医院

Primary sponsor:

Beijing Hospital

研究实施负责(组长)单位地址:

北京东单大华路1号

Primary sponsor's address:

1 Dahua Road, Dongdan, Beijing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

北京医院

具体地址:

北京东单大华路1号

Institution
hospital:

Beijing Hospital

Address:

1 Dahua Road, Dongdan, Beijing

经费或物资来源:

首都卫生发展科研专项

Source(s) of funding:

Capital Health Development Research Programme

Target disease:

respiratory infection

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

I期临床试验 

Study phase:

1

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

描绘老年呼吸道感染后机体恢复期多维度指标变化规律和轨迹; 评价基于多维度评估的个体化干预策略对改善老年呼吸道感染后生活质量效果。  

Objectives of Study:

To depict the pattern of change and trajectory of multidimensional indicators during the organism's recovery period after respiratory infection in the elderly; To evaluate the effect of individualised intervention strategies based on multidimensional assessment on improving quality of life after respiratory infection in the elderly.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

筛查标准: 1. 年龄≥65岁; 2. 因急性下呼吸道感染住院患者,急性下呼吸道感染包括急性气管-支气管炎、社区获得性肺炎、慢性支气管炎或慢性阻塞性肺疾病急性加重、支气管扩张合并感染、肺间质纤维化合并感染; 3. 本机构住院。 入选标准: 为满足筛选、排除标准后,出院时EQ-5D-5L存在至少一个维度受损(评估水平>1)的老年急性呼吸道感染患者。

Inclusion criteria

Screening criteria: 1. Aged ≥65 years; 2. Patients hospitalised for acute lower respiratory tract infections, which include acute tracheo-bronchitis, community-acquired pneumonia, acute exacerbation of chronic bronchitis or chronic obstructive pulmonary disease, bronchiectasis co-infections, and interstitial fibrosis co-infections; 3. Hospitalisation in this institution. Inclusion criteria: patients whom at least one dimension of the EQ-5D-5L was present and impaired (assessed at level >1) at the time of discharge from the hospital after meeting the above screening and exclusion criteria.

排除标准:

1. 年龄>100岁; 2. 因各种原因(严重认知功能障碍、失聪、非汉语等)无法配合完成问卷及随访; 3. 慢性感染包括肺结核、肺部真菌感染、细菌性肺脓肿等; 4. 急性心梗(1个月内)、不稳定心绞痛、未控制的心律失常、感染性心内膜炎或心包炎活动期、重度主动脉瓣狭窄、未控制心衰、未控制高血压(静息收缩压>180mmHg,舒张压>100mmHg)、可疑动脉瘤夹层; 5. 急性肺栓塞或肺梗死、下肢深静脉血栓;未控制哮喘、呼吸衰竭;近1年自发气胸史或气胸未控制; 6. 既往有精神异常或正在接受精神科治疗,既往有人格障碍、智力障碍、脑损伤或脑部疾病者; 7. 合并神经肌肉等系统疾病或其他严重的运动障碍,如关节畸形、疾病或严重的脊椎关节疼痛等影响身体活动的疾病者; 8. 在过去6个月内参加过其他康复研究; 9. 目前参加其他干预性临床试验(参加观察性临床试验可纳入); 10. 合并严重基础疾病,预期生存寿命<1年; 11. 长期卧床; 12. 住院期间死亡。

Exclusion criteria:

1. Aged >100 years; 2. Unable to co-operate in completing the questionnaire and follow-up for various reasons (severe cognitive impairment, deafness, non-Chinese speaking, etc.); 3. Chronic infections including tuberculosis, fungal infections of the lungs, bacterial lung abscess, etc; 4. Acute heart attack (within 1 month), unstable angina pectoris, uncontrolled arrhythmia, active stage of infective endocarditis or pericarditis, severe aortic stenosis, uncontrolled heart failure, uncontrolled hypertension (resting systolic blood pressure >180mmHg, diastolic blood pressure >100mmHg), suspected aneurysm entrapment; 5. Acute pulmonary embolism or pulmonary infarction, lower extremity deep vein thrombosis; uncontrolled asthma, respiratory failure; history of spontaneous pneumothorax in the last 1 year or uncontrolled pneumothorax; 6. Previous psychiatric abnormality or under psychiatric treatment; previous personality disorder, mental retardation, brain injury, or brain disease 7. Persons with comorbid neuromuscular and other systemic disorders or other severe movement disorders such as joint deformities, diseases, or severe spinal joint pains that interfere with physical mobility 8. Who have participated in other rehabilitation studies within the past 6 months 9. Current participation in other interventional clinical trials (participation in observational clinical trials may be included); 10. Comorbid serious underlying disease with a life expectancy of survival of <1 year; 11. Prolonged bed rest; 12. Death during hospitalisation.

研究实施时间:

Study execute time:

From 2024-01-01 00:00:00 To 2026-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-06-01 00:00:00 To 2025-05-31 00:00:00  

干预措施:

Interventions:

组别:

干预组

样本量:

153

Group:

Intervention group

Sample size:

干预措施:

基于综合评估的个性化康复方案

干预措施代码:

Intervention:

Individualised rehabilitation programmes based on comprehensive assessment

Intervention code:

组别:

对照组

样本量:

153

Group:

control group

Sample size:

干预措施:

常规抗感染诊疗方案

干预措施代码:

Intervention:

Routine anti-infective treatment programme

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China 

Province:

Beijing 

City:

 

单位(医院):

北京医院 

单位级别:

三甲 

Institution
hospital:

Beijing Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China 

Province:

Beijing 

City:

 

单位(医院):

首都医科大学附属朝阳医院 

单位级别:

三甲 

Institution
hospital:

Chaoyang Hospital of Capital Medical University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China 

Province:

Beijing 

City:

 

单位(医院):

北京市东城区第一人民医院 

单位级别:

三级 

Institution
hospital:

The First People's Hospital of Dongcheng District, Beijing

Level of the institution:

Tertiary

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China 

Province:

Beijing 

City:

 

单位(医院):

北京市隆福医院 

单位级别:

三级 

Institution
hospital:

Beijing Longfu Hospital

Level of the institution:

Tertiary

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China 

Province:

Beijing 

City:

 

单位(医院):

北京市朝阳区六里屯社区卫生服务中心 

单位级别:

社区卫生服务中心 

Institution
hospital:

Liulitun Community Health Service Centre, Chaoyang District, Beijing, China

Level of the institution:

Community Health Service Cente

测量指标:

Outcomes:

指标中文名:

生活质量

指标类型:

主要指标

Outcome:

quality of life

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

死亡

指标类型:

次要指标

Outcome:

death

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

再入院

指标类型:

次要指标

Outcome:

re-hospitalization

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

日常活动能力

指标类型:

次要指标

Outcome:

Ability to perform daily activities

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

认知能力

指标类型:

次要指标

Outcome:

cognitive ability

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

情绪障碍

指标类型:

主要指标

Outcome:

emotional disorder

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

营养

指标类型:

次要指标

Outcome:

nutrition

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

跌倒

指标类型:

次要指标

Outcome:

fall

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

免疫

指标类型:

次要指标

Outcome:

immune

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

评估时间

指标类型:

次要指标

Outcome:

time to assessment

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 65 years
最大 Max age 100 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

由系统随机数随机,北京医院中心随机,无法人为干预

Randomization Procedure (please state who generates the random number sequence and by what method):

Randomised by systematic random numbers, randomised by Beijing Hospital Centre, unable to consider intervention

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

本研究采用单盲实验设计。研究对受试者、干预实施者不设盲,对评估实施者及数据整理分析者实施盲法。本研究中一位研究者不能同时进行评估及干预工作,评估实施者及干预实施者不能互相沟通,干预者仅通过每月智能平台或电话获取患者多维度评估结果。对照组受试者及干预受试者接受评估的内容及时间间隔均一致,评估实施者进行评估时无法获知受试者分组信息。在系统中,疗效评估者和干预者分别拥有独立的界面,二者之间无法进行通信或交流。

Blinding:

This study used a single-blind experimental design. The study was unblinded to subjects and intervention implementers, and blinded to assessment implementers and data collation and analysis. In this study, one researcher could not conduct both assessment and intervention work, the assessment implementer and intervention implementer could not communicate with each other, and the interventionist only accessed the multidimensional assessment results of the patients through the monthly smart platform or by phone. Control subjects and intervention subjects were assessed at the same content and time intervals, and the assessment implementer was not able to obtain information about the grouping of subjects when conducting the assessment. In the system, the efficacy assessor and the interventionist had separate interfaces, and there was no communication or exchange between them.

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

NA

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

NA

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据采集通过CRF表,管理通过EDC系统

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data collection through CRF table, management through EDC system

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2024-05-30 10:29:47